Peptide Pen SLU-PP-332

SLU-PP-332 is a first-in-class synthetic small-molecule pan-agonist of estrogen-related receptors (ERRA, ERRẞ, and ERRY). It is a non-steroidal, non-endocrine-disrupting compound belonging to the class of ERR agonists. Chemical name: 4-hydroxy-N-(4-(2-(4-hydroxyphenyl)propan-2-yl)phenyl)benzamide (or structural analog thereof; exact proprietary structure is patented by Saint Louis University). SLU-PP-332 is orally bioavailable, metabolically stable, and designed to selectively activate ERRS without binding classical estrogen receptors (ERa/ERẞ). Mechanism of Action SLU-PP-332 binds directly to the ligand-binding domain of ERRA, ERRẞ, and ERRY, inducing conformational changes that promote coactivator recruitment (e.g., PGC-1a) and transcriptional activation of ERR target genes. Key downstream effects include: Upregulation of mitochondrial biogenesis and oxidative phosphorylation genes Increased expression of fatty acid oxidation enzymes and mitochondrial uncoupling proteins Enhanced type I (slow-twitch, oxidative) muscle fibre gene programs Improved exercise endurance capacity and metabolic flexibility Activation of energy expenditure pathways independent of classical estrogen signalling The compound induces an “exercise-like” molecular signature in skeletal muscle, liver, adipose tissue, and brain, mimicking many of the metabolic adaptations seen with chronic physical training. Indications & Usage SLU-PP-332 is used to support mitochondrial function, metabolic health, and exercise-like adaptations. It is indicated for: Enhancement of mitochondrial biogenesis and cellular energy production Promotion of fat oxidation, metabolic efficiency, and insulin sensitivity Support for endurance capacity, muscle oxidative phenotype, and recovery from metabolic stress Assistance in age-related or inactivity-related decline in mitochondrial and metabolic performance Contraindications & Warnings Do not use if you have: Known hypersensitivity to SLU-PP-332 or any excipient Active malignancy (theoretical concern regarding enhanced cellular metabolism) Severe uncontrolled hepatic or renal impairment Pregnancy or breastfeeding Age under 18 years